Digoxin: Cardiac Glycoside and Na+/K+ ATPase Inhibitor for Heart Failure and CHIKV Research

Executive Summary: Digoxin is a well-characterized cardiac glycoside that inhibits the Na+/K+ ATPase pump, increasing intracellular sodium and calcium to enhance cardiac contractility (APExBIO). It is widely used in research on heart failure, arrhythmias, and antiviral mechanisms, particularly against chikungunya virus (CHIKV) in cell culture models (Vero, U-2 OS, and human synovial fibroblasts). Digoxin demonstrates dose-dependent antiviral effects at 0.01–10 μM and is provided at high purity (>98.6%) for reproducible experimental outcomes. Its solubility profile (≥33.25 mg/mL in DMSO, insoluble in water and ethanol) and validated animal model data (canine congestive heart failure) support robust translational workflows. Benchmarks and pitfalls are detailed herein for optimal deployment in cardiovascular disease and virology research (Sun et al. 2025).

Biological Rationale

Cardiac glycosides like Digoxin are essential tools for dissecting the Na+/K+ ATPase signaling pathway, which regulates cardiac contractility and electrophysiology. By inhibiting this membrane-bound enzyme, Digoxin modulates ion gradients, leading to increased intracellular calcium via the sodium-calcium exchanger. This mechanism is fundamental in heart failure and arrhythmia models. Additionally, Digoxin has emerged as an antiviral agent, with evidence showing impairment of CHIKV infection in several human and animal cell lines at micromolar concentrations (APExBIO).

Beyond direct cardiac effects, the Na+/K+-ATPase pump is implicated in wider signal transduction and cell viability pathways. Research on Digoxin contributes to the understanding of cardiovascular disease mechanisms and the development of antiviral strategies (see related; this article adds in-depth benchmarking and updated pharmacokinetic perspectives).

Mechanism of Action of Digoxin

Digoxin binds to the extracellular domain of the Na+/K+-ATPase pump, inhibiting its activity. This results in the accumulation of intracellular sodium. Consequently, the sodium-calcium exchanger operates less efficiently, leading to increased intracellular calcium. Elevated calcium levels enhance contractile force in cardiomyocytes, which is the primary therapeutic rationale for Digoxin in heart failure research (see also; this article updates mechanistic detail and experimental parameters).

In virology models, Digoxin's inhibition of Na+/K+-ATPase disrupts viral entry and replication, particularly for CHIKV. The compound’s activity has been characterized as dose-dependent, with measurable effects at 0.01–10 μM in cell lines including U-2 OS and primary human synovial fibroblasts (APExBIO).

Evidence & Benchmarks

• Digoxin at concentrations from 0.01–10 μM impairs chikungunya virus infection in U-2 OS, human synovial fibroblasts, and Vero cells (APExBIO, product page).
• In canine congestive heart failure models, intravenous Digoxin (1–1.2 mg) increases cardiac output and reduces right atrial pressure (APExBIO, product page).
• Digoxin is insoluble in water and ethanol but is soluble at ≥33.25 mg/mL in DMSO, supporting high-concentration stock preparations (APExBIO, product page).
• High-purity Digoxin (>98.6%) is validated by HPLC and NMR, enabling reproducible results across research settings (see interlinked article; this update provides current QC parameters).
• Recent pharmacokinetic studies emphasize the need for tailored dosing regimens in disease models with altered transporter or enzyme expression (Sun et al., 2025).

Applications, Limits & Misconceptions

Digoxin’s main applications include:

• Cardiac contractility modulation in heart failure and arrhythmia models.
• Mechanistic studies of the Na+/K+ ATPase signaling pathway.
• Antiviral assays targeting CHIKV in human and animal cell lines.
• Animal model validation (e.g., canine congestive heart failure).

Recent translational studies highlight the dual role of Digoxin, bridging cardiovascular and infectious disease research (see related article; this article offers updated limits and integration guidance).

Common Pitfalls or Misconceptions

• Digoxin is not effective as a primary antiviral therapy in vivo; its use is limited to in vitro and preclinical models.
• Long-term storage of Digoxin solutions is not recommended; solutions should be prepared fresh for each experiment (APExBIO, product page).
• Water or ethanol should not be used as solvents for Digoxin due to insolubility; use DMSO at ≥33.25 mg/mL for stock preparation.
• Pharmacokinetic behavior may vary in disease models with altered expression of transporters or CYP enzymes (Sun et al., 2025).
• Digoxin’s effects in animal models may not directly translate to human clinical outcomes without additional validation.

Workflow Integration & Parameters

Digoxin (SKU B7684, APExBIO) is supplied as a solid with >98.6% purity, accompanied by HPLC, NMR, and MSDS documentation. Stock solutions should be prepared in DMSO at concentrations ≥33.25 mg/mL. For cell-based assays, working concentrations typically range from 0.01–10 μM, with prompt use after dilution. For animal studies, dosing regimens (e.g., 1–1.2 mg intravenous in canine models) must be tailored to species, weight, and experimental endpoints.

Quality control ensures batch-to-batch reproducibility. Researchers should reference recent pharmacokinetic insights to adjust protocols in models of metabolic dysfunction or altered transporter expression (Sun et al., 2025).

For scenario-driven guidance and troubleshooting, see this workflow article; our current article expands application scope and parameter details.

Conclusion & Outlook

Digoxin remains a validated, high-purity standard for research into cardiac contractility, arrhythmias, and virology. Its dual mechanistic impact on Na+/K+ ATPase signaling and CHIKV inhibition is supported by robust benchmark data and recent pharmacokinetic analyses. APExBIO provides Digoxin (SKU B7684) with comprehensive documentation for reproducibility and workflow integration. Ongoing research should continue to refine dosing and model selection, especially in the context of metabolic disease and transporter variability (Sun et al., 2025).

For full product specifications and ordering, visit the Digoxin product page.